


PHARMACEUTICAL 2021



Prelude Therapeutics Inc Rank 35 of 402





PHARMACEUTICAL 2021



Prelude Therapeutics Inc Rank 35 of 402



The relative strengths and weaknesses of Prelude Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Prelude Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 79% points. The greatest weakness of Prelude Therapeutics Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 262%, being 215% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	220,809
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,375
Liabilities, Non-Current	32
Other Assets	301
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	1,834
Other Revenues	0
Property and Equipment	2,480
Research and Development	48,177
Selling, General and Administrative Expense	10,586

Output Variable	Value in 1000 USD
Assets	223,590
Liabilities	11,407
Expenses	58,763
Revenues	0
Stockholders Equity	212,183
Net Income	-56,929
Comprehensive Net Income	-56,929
Economic Capital Ratio	262%

